rethinkPeptides Search
Menu
Study breakdown

Can GLP-1 Drugs Reduce Inflammation Linked to Knee Osteoarthritis in Overweight Patients?

RctModerate evidence
The takeaway

Weight loss and liraglutide treatment were evaluated for their effects on NGAL, an inflammatory marker linked to osteoarthritis, in overweight patients with knee OA.

52-week trial

Randomized placebo-controlled assessment of liraglutide effects on inflammatory OA biomarker NGAL

What the researchers found

Study evaluated whether diet-induced weight loss and subsequent liraglutide treatment reduce NGAL, a proinflammatory biomarker linked to osteoarthritis.

Why it matters

If GLP-1 drugs reduce inflammatory markers driving joint disease, they could address both obesity and osteoarthritis simultaneously.

The numbers in context

N=168 enrolled, 127 randomized; NGAL rose 93.0 ng/mL (95% CI: 18.9-167.1, P=0.015) after 8-week diet; no difference between liraglutide and placebo at 52 weeks.

How the study worked

Secondary analysis of a randomized, double-blind, placebo-controlled trial (8-week LCD + 52-week liraglutide 3 mg vs. placebo).

Who was studied

Adults with BMI >=27 and symptomatic knee osteoarthritis

What this study cannot tell us

Secondary/exploratory analysis — not powered for NGAL as primary endpoint. Single biomarker does not capture full OA pathophysiology.

How to read the evidence

Secondary analysis of a well-designed RCT — robust design but exploratory endpoint limits strength of conclusions.

When this study was published

Published in 2025, exploring an emerging connection between GLP-1 drugs and joint health.

The bigger picture

This positions GLP-1 drugs at the intersection of metabolic and musculoskeletal disease, expanding their potential therapeutic reach.

Questions still open

  • Does NGAL reduction translate to improved joint symptoms?
  • Would longer GLP-1 treatment show greater NGAL effects?

Common questions

Could GLP-1 drugs help with arthritis?
This study examined whether liraglutide reduces an inflammatory marker (NGAL) linked to osteoarthritis — a promising but early-stage question.
What is NGAL?
A protein released by fat tissue that promotes inflammation and may contribute to osteoarthritis development in overweight individuals.

Read the original research

Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.

Osteoarthritis and cartilage open, 7(1), 100562

Citation

Poulsen, Asbjørn Seenithamby; Stisen, Zara Rebecca; Skougaard, Marie; Christensen, Robin; Overgaard, Anders; Gudbergsen, Henrik; Jacobsen, Stine; Balslev-Clausen, Andreas Peter; Henriksen, Marius; Kristensen, Lars Erik; Bliddal, Henning. (2025). Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.. Osteoarthritis and cartilage open, 7(1), 100562. https://doi.org/10.1016/j.ocarto.2024.100562